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BACKGROUND: Antibiotic resistance has become a worldwide problem. Among Asia countries, Indonesia has high prevalence of multi-drug 
resistant organisms mainly due to Gram-negative bacilli 
Enterobacteriaceae.  This study aimed to find out whether 
gene family of AmpC and AmpC/ESBL-producing 
Enterobacteriaceae  were  present  in  the  Intensive  Care 
Unit (ICU) of Cipto Mangunkusumo Hospital, Jakarta, 
Indonesia. 
METHODS: Specimens were obtained from several body 
sites of adult patients with infection hospitalised in ICU 
of Cipto Mangunkusumo Hospital. VITEK®2 was used 
to identify the microorganisms. Antibiotic susceptibility 
tests were conducted using VITEK®2 and disc diffusion 
technique according to Clinical and Laboratory Standards 
Institute (CLSI) guidelines. Double disc synergy (DDS) 
test method was employed to detect AmpC activity. 
Gene families of ampC were identified using multiplex 
polymerase chain reaction (PCR).
RESULTS: Forty five isolates were identified as putative 
AmpC, extended-spectrum β-lactamases (ESBL) and 
AmpC/ESBL-producing Enterobacteriaceae. Klebsiella 
pneumoniae (n=32) were predominant, followed by 
Escherichia coli (n=6), Enterobacter cloacae (n=5) and 
Enterobacter aerogenes (n=2).  AmpC activity was detected 
in 9 isolates, in which 4 isolates were AmpC producing and 
5 isolates were AmpC/ESBL. In vitro, AmpC-producing 
Enterobacteriaceae showed good susceptibility to many 
antibiotic tested, while those of AmpC/ESBL-producing 
only to Amikacin. The gene families of ampC were DHA, 
EBC and CIT identified from 6 isolates.
CONCLUSION: DHA, EBC and CIT gene families 
were identified from AmpC and AmpC/ESBL-producing 
Enterobacteriaceae in the ICU of Cipto Mangunkusumo 
Hospital. While the AmpC-producing was still susceptible 
to almost all antibiotics tested, the AmpC/ESBL-producing 
showed resistant except for Amikacin.
KEywORDS: Enterobacteriaceae, β-lactamases, AmpC, 
ESBL
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Abstract
Introduction
Antimicrobial resistance has become a serious problem 
worldwide, especially in Asia.(1) Indonesia is one of 
the Asian countries where the prevalence of multi drug-
resistant organisms (MDRO) is very high. The high 
resistance rates is mainly found in Gram-negative bacteria 
such as Pseudomonas aeruginosa, Enterobacteriaceae 
and Acinetobacter baumannii. The same situation applies 
in animal farms.(2) The resistance rates of Klebsiella 
pneumoniae, Klebsiella ozaenae and Escherichia coli 
isolated from Intensive Care Unit (ICU) of Fatmawati 
Hospital were 75.7%, 81.5% and 46.2% to Ceftriaxone; 
67.9%, 100% and 46.2% to Cefotaxime; 73%, 85.7% 
and 38.5% to Ceftazidime.(3) In the ICU of Cipto 
Print ISSN: 2085-3297, Online ISSN: 2355-9179The Indonesian Biomedical Journal, Vol.11, No.1, April 2019, p.107-12
108
Mangunkusumo Hospita, Jakarta, however, the prevalence 
of carbapenem resistant i.e., Enterobacteriaceae 27.6%, P. 
aeruginosa 21.9% and A. baumannii 50.5%.(4)
 The major mechanism of resistance of Gram-negative 
bacteria is from the production of β-lactamases, such as AmpC 
β-lactamases (AmpC) and extended spectrum β-lactamases 
(ESBL).(5) The AmpC producers confer resistance to 
penicillins, cephamycins (i.e., Cefoxitin, Cefotetan), 
oxyimino-cephalosporins (i.e., Ceftazidime, Cefotaxime, 
Ceftriaxone) and monobactams (i.e., Aztreonam). This 
type of microorganism shows resistant to antibiotic com-
bination of β-lactam and β-lactamase inhibitors i.e., 
Amoxicillin/Clavulanic acid.  The AmpC β-lactamases are 
chromosomal-mediated, and many Gram-Negative bacteria 
such as Enterobacter spp., Citrobacter spp., Serratia spp., 
Morganella morganii, Aeromonas spp. and Hafnia alvei 
have been known to produce AmpC β-lactamases.(6,7,8) 
The widely use of β-lactam antibiotics and  β-lactamase 
inhibitors induces a high level expression of chromosomal-
mediated AmpC and causes the resistant to among other 
the 3rd generation of cephalosporin and carbapenem. In 
hospitals where 3rd generation cephalosporins are being 
used repeatedly for a long period of time, the problem of 
antibiotic resistance arise. Enterobacter aerogenes and 
Enterobacter cloacae which are initially susceptible to 3rd 
generation cephalosporins have become resistant upon 
therapy.(8)
 Apart from the chromosomal gene, the AmpC is 
also encoded by the plasmid. Gram-negative bacteria 
such as Klebsiella oxytoca, Proteus mirabilis, Citrobacter 
freundii and Enterobacter aerogenes are among those 
with plasmid-mediated AmpC.(8,9,10,11) Differ from 
chromosomal-mediated AmpC, plasmid-mediated AmpC 
are expressed significantly, and are typically associated with 
broad multidrug resistance.(10,11) The microorganisms 
that are over expressing AmpC can become resistant 
to carbapenem when there is disturbance of the outer 
membrane permeability.(6)  At present, 6 types of plasmid-
mediated ampC gene family has been found, namely DHA 
(firstly isolated at Dhahran Hospitals in Saudi Arabia), EBC 
(isolated from Enterobacter cloacae), CIT (firstly isolated 
from Citrobacter freundii), Ambler class C (ACC), FOX 
(Active on Cefoxitin), and MOX (Active on Moxalactam).
 In the past decades, the prevalence of AmpC-
producing Enterobacteriaceae had increased, and resulted in 
a serious threat, among other these bacteria are the major 
cause of hospital-acquired infections.(12,13)  However, the 
information regarding AmpC-producing Enterobacteriaceae 
originated from hospitalised patients in Indonesia is not 
available thus far.  This study aimed to explore the presence 
of AmpC-β-lactamase producing Enterobacteriaceae gene 
family in the ICU of Cipto Mangunkusumo Hospital, 
Jakarta, and also their antibiotic susceptibility.
Methods
This was a descriptive and cross sectional study. Clinical 
specimens i.e., blood, lower respiratory tract secretions, 
urine, wound swabs, pus and soft tissues obtained from adult 
patients with infection in the ICU of Cipto Mangunkusumo 
Hospital within 6 months from April to September 2015 
were subjected for the investigation. Bacterial cultivation 
workup was performed in the Clinical Microbiology 
laboratory of the Department of Microbiology, Faculty of 
Medicine, Universitas Indonesia. All patients that agreed to 
give their specimens were enrolled in this study, and signed 
informed consent.
Bacterial Isolates
Bacterial identification was conducted using VITEK®2 
(Bio-Mérieux, Craponne, France).  Anti-biotic susceptibility 
tests were conducted using VITEK®2 for Ampicillin, 
Gentamicin, To-bramycin, Amikacin, Ampicillin/
Sulbactam, Piperacillin/Tazobactam, Cefoxitin, Cefotaxime, 
Ceftazidime, Cefepime, Meropenem, Ciprofloxacin, 
Levofloxacin, Fosfomycin, Tetracycline,  Cotrimoxazole. 
As for Ceftriaxone, Cefpodoxime, and Aztreonam, disc 
diffusion technique was employed according to Clinical 
and Laboratory Standards Institute (CLSI) 2014 guidelines.
(14) The antibiotic activity was classified as good if the 
susceptibility of all isolates to the antibiotic was 80% or 
greater.  Isolates which less susceptible or resistant to one or 
more of 3rd generation cephalosporins (i.e., Cefpodoxime, 
Ceftazidime, Cefotaxime, Ceftriaxone) and/or Aztreonam 
and/or resistance to Cefoxitin were considered as putative 
AmpC β-lactamases, ESBL or AmpC/ESBL producers, 
and were included in this study. These isolates underwent 
confirmation test i.e., double disc synergy test (DDS) for 
AmpC β-lactamases and ESBL and subjected to multiplex 
polymerase chain reaction (PCR) for the detection of ampC 
gene families.
Confirmation Tests for AmpC β-lactamases and ESBL 
Using DDS Test
DDS test method using Total ESBL+AmpC kit 98019 
(ROSCO Diagnostica, Taastrup, Denmark) was employed to 
detect AmpC and ESBL activity. The assay was performed 
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according to recommendations in the user manual. 
Antibiotic discs used were Cefotaxime + Cloxacillin 
(CTXCX), Cefotaxime + Clavulanate (CTXC), Cefotaxime 
+ Clavulanate + Cloxacillin (CTXCC), Ceftazidime + 
Cloxacillin (CAZCX), Ceftazidime + Clavulanate (CAZC) 
and Ceftazidime + Clavulanate + Cloxacillin (CAZCC). 
Isolates were confirmed as AmpC-producing when the 
inhibition zone produced around CTXC/CTXCC and/
or CAZC/CAZCC discs was differ ≥ 5 mm. An ESBL-
producing was confirmed if the inhibition zone produced 
around the CTXCX/CTXCC and/or CAZCX/CAZCC 
discs was ≥ 5 mm.  If the inhibition zones produced around 
CTXCX/CTXCC and the CTXC/CTXCC discs were differ 
≥ 5 mm, and/or the CAZCX/CAZCC and CAZC/CAZCC 
discs were ≥ 5 mm then they were confirmed as producing 
both AmpC/ESBL enzymes.  Escherichia coli ATCC 25922 
was used as quality control strain.
 The proportion of AmpC and AmpC/ESBL-producing 
Enterobacteriaceae was determined by dividing the number 
of those obtained from DDS test with all putative isolates 
which were less susceptible or resistant to one or more of 
3rd generation cephalosporins and/or Aztreonam and/or 
resistance to Cefoxitin.
Multiplex PCR for the Identification of AmpC Gene 
Families
The DNA extraction was performed from fresh culture using 
boiling techniques.  Five to 10 colonies of overnight bacterial 
culture were suspended into 500 μL of sterile phosphate 
buffer saline (PBS), mixed on a vortex mixer, and spin at 
12,000 rpm for 2 min (2 times).  After the supernatant was 
decanted, the pellet was resuspended in 200 μL of TE buffer 
and the mixture was briefly mixed on a vortex mixer. The 
cells were lysed by heating at 90°C for 20 min and cellular 
debris was removed by centrifugation at 12,000 rpm for 10 
min. A 100 μL aliquot of the supernatant was transferred to a 
sterile tube and stored at -20°C until PCR testing.  Multiplex 
PCR (Philisa® ampC ID Kit, Streck, Inc., La Vista, USA) 
was conducted to detect 6 different families of plasmid-
mediated ampC genes i.e., ACC, CIT, DHA, EBC, FOX 
and MOX, and primers were used as published earlier.(7) 
The assay was performed according to recommendations in 
the user manual.
Ethical Clearance
This study has passed ethical evaluations by the Faculty 
of Medicine, Universitas Indonesia No. 51/UN2.F1/
ETIK/2015 and Cipto Mangunkusumo Hospital Ethics 
Committee No. LB.02.01/X.2/105/2015.
Sputum Wound Swab Blood Urine
Abscess 
Aspirate
Total, 
n (%) AmpC ESBL
AmpC 
ESBL
Non-
producing
K . pneumoniae 27 3 2 0 0 32 (71.1) 1 27 2 2
E . coli 2 1 0 2 1 6 (13.4) 0 5 1 0
E . cloacae 4 1 0 0 0 5 (11.1) 2 0 2 1
E . aerogenes 1 0 1 0 0 2 (4.4) 1 1 0 0
Total, n (%) 34 (75.6) 5 (11.1) 3 (6.7) 2 (4.4) 1 (2.2) 45 (100) 4 33 5 3
Specimen Types (%)
Bacteria
Double Disc Synergy Test
Table 1.  Species bacteria isolated, type of specimen and AmpC-producing Enterobacteriaceae determined by DDS 
test taken from patients in the ICU of Cipto Mangunkusumo Hospital. 
A total of 370 clinical specimens were collected from 
patients with infections in the ICU of Cipto Mangunkusumo 
Hospital from April 2015 to September 2015. After the 
cultivation and bacterial identification processes 63 isolates 
were identified as Enterobacteriaceae, and tested further 
for antibiotic  susceptibility. The results showed 45 isolates 
composed of K. pneumoniae, E. coli, E. cloacae and E. 
aerogenes with decreased susceptibility to one or more of 
the 3rd generation cephalosporins and/or Aztreonam and/or 
resistance to Cefoxitin. Among those 4 species, Klebsiella 
pneumoniae was the most prominent (71.1%) and sputum 
was the main source of isolates (75.6%) (Table 1).  
 The DDS test was employed to these 45 isolates and 
the results were shown in Table 1, as follow: Four isolates 
were the AmpC-producing Enterobacteriaceae i.e., K. 
pneumoniae (n=1), E. cloacae (n=2), and E. aerogenes 
(n=1).  Thirty three isolates were the ESBL-producers in 
which K. pneumoniae was the most prominent among 
other Enterobactericeae. Five isolates were the AmpC/
Results
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ESBL producers i.e., K. pneumoniae (n=2), E. cloacae 
(n=2) and E. coli (n=1).  Three isolates were non-producing 
β-lactamases. In brief, out of 45 isolates of the putative 
AmpC β-lactamases and/or ESBL producers, only 9 (20%) 
isolates were confirmed by DDS test as the AmpC and 
AmpC/ESBL producers.
 Antibiotic susceptibility tests were carried out as 
mentioned in the methods for the 42 AmpC, ESBL, and 
AmpC/ESBL confirmed isolates. Three isolates of the 
non-producing β-lactamases were not tested. As shown in 
Tables 2, the AmpC-producing isolates (4 isolates) showed 
≥75% susceptibility to Gentamicin, Tobramycin, Amikacin, 
Cefepime, Meropenem, Ciprofloxacin, Levofloxacin, 
Tetracycline and Cotrimoxazole. All 5 isolates of the AmpC/
ESBL-producing isolates showed resistant to all antibiotics 
but to Amikacin. 
 Gene family of AmpC-producing Enterobacteriaceae 
was  determined  by multiplex  PCR  on  all of 45 
isolates (Figure 1).   The results showed that ampC genes 
were detected in 6 isolates consisted of 4 species i.e., K. 
pneumoniae, E. cloacae, E. aerogenes and E. coli.  The 
ampC gene families, i.e., DHA, EBC and CIT were 
identified. DHA gene family was identified from 2 isolates 
AmpC (%)
(n=4)
ESBL (%)
(n=33)
AmpC/ESBL (%)  
(n=5)
Ampicillin 0 0 0
Ampicillin/sulbactam 0 0 0
Piperacillin/tazobactam 25 42 20
Cefoxitin 0 58 0
Cefotaxime 25 0 0
Ceftriaxone 25 0 0
Cefpodoxime 25 0 0
Ceftazidime 25 0 0
Cefepime 75 0 20
Meropenem 75 73 40
Aztreonam 50 9 0
Ciprofloxacin 75 9 0
Levofloxacin 75 15 20
Gentamicin 100 24 40
Tobramycin 75 6 20
Amikacin 100 76 100
Tetracycline 75 21 0
Trimethoprim/sulphamethoxazole 75 33 20
Fosfomycin 50 88 40
Antibiotic
Beta-lactams
Quinolones
Aminoglycosides
Others
Table 2.  Antimicrobial susceptibility patterns of the AmpC, ESBL and both 
AmpC/ESBL producing Enterobacteriaceae.
of K. pneumoniae and 1 isolate of E. cloacae. EBC was 
from 1 isolate each of E. cloacae and of E. aerogenes, and 
lastly CIT was from 1 isolate of E. coli (Table 3).
Discussion
This study demonstrates that gene families of AmpC-
producing Enterobacteriaceae are present in the ICU of 
Cipto Mangunkusumo Hospital, Jakarta. The distribution of 
the total proportion of AmpC-producing Enterobacteriaceae 
was 20%, consisting of 9 isolates out of 45  putative putative 
AmpC β-lactamases and/or ESBL producers. The result was 
quite similar with previous studies carried in India, Singapore 
and South Korea.(8,9,12,15) Our study showed that among 9 
isolates of the AmpC producers, 5 of them produced AmpC 
and ESBL. Unlike the AmpC/ESBL producers that showed 
resistant to all antibiotics except for Amikacin, the AmpC-
producing isolates were susceptible to many antibiotics 
such as Gentamicin, Tobramycin, Amikacin, Cefepime, 
Meropenem, Ciprofloxacin, Levofloxacin, Tetracycline, 
and Cotrimoxazole.  In this study, 1 of the AmpC-producing 
isolate and 3 AmpC/ESBL-producing isolates showed 
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CI       CII        1          2          3         C(-)       M
600 bp
300 bp
100 bp
MOX 520 bp
DHA 405 bp
ACC 346 bp
EBC 302 bp
FOX 247 bp
IC 196 bp
CIT 106 bp
CI       CII        1          2          3         C(-)       M
600 bp
300 bp
100 bp
MOX 520 bp
DHA 405 bp
ACC 346 bp
EBC 302 bp
FOX 247 bp
IC 196 bp
CIT 106 bp
Figure 1.  Multiplex PCR for ampC gene 
family. Lane C I: Positive control I:  MOX (520 
bp), ACC (346 bp), FOX (247 bp). Lane C II: 
Positive control II: DHA (405 bp), EBC (302 
bp), CIT (160 bp). Lane C (-): Negative control. 
Lane 1, 2, 3: Samples with DHA positive, EBC 
positive and  CIT positive respectively. Lane 
M: Standard DNA ladder for molecular size. 
MOX, DHA, ACC, EBC, FOX, and CIT are 
ampC gene gamily (DHA: firstly isolated in 
Dhahran  Hospitals Saudi Arabia, EBC: isolated 
from Enterobacter cloacae, CIT: firstly isolated 
from Citrobacter freundii, ACC: Ambler class C, 
FOX: Active on Cefoxitin, and MOX: Active on 
Moxalactam, IC: internal control).
Gene Family DDS Test EnterobacteriaceaeSpecies
AmpC/ESBL Enterobacter cloacae
AmpC/ESBL Klebsiella pneumoniae
AmpC Klebsiella pneumoniae
AmpC Enterobacter cloacae
AmpC Enterobacter aerogenes
CIT AmpC/ESBL Escherichia coli
Not detected AmpC/ESBL Klebsiella pneumoniae
Not detected AmpC/ESBL Enterobacter cloacae
Not detected AmpC Enterobacter cloacae
DHA 
EBC
Table 3. Detection of gene family of AmpC-
producing Enterobacteriaceae from 6 isolates 
phenotypically confirmed by DDS test.
decreased susceptibility to Meropenem. This results 
might suggest that these microbes carry another resistance 
mechanism, such as porin loss.(6)  Porins play a critical 
role in the penetration of antibiotics into the cells, and the 
loss of porins can reduce susceptibility to cephalosporins 
and carbapenem. Porins loss are associated with boosting 
the resistance to carbapenem by means of ESBL and AmpC 
β-lactamases.(16)
 Up until today, studies about molecular epidemiology 
of resistance pathogens in Indonesia were still limited. To 
our knowledge, our study was the first investigation about 
the gene family of AmpC-producing Enterobacteriaceae in 
Indonesia. Using the multiplex PCR, DHA, EBC and CIT 
gene families of the AmpC-producing were identified.  The 
DHA gene family seemed to be more common than EBC 
and CIT.  Our results were in agreement with other studies 
carried in India that found the CIT and DHA gene families.
(9,10,11)  In Singapore, the presence of CIT gene family was 
reported while the EBC and DHA gene families have been 
found in Malaysia.(10,17)  Other reports from Thailand (18) 
and South Korea (12) showed the presence of CIT, MOX, 
DHA and CIT respectively. 
 Hansen, et al., 2012 identified DHA gene family of 
AmpC-producing K. pneumoniae, however, the β-lactamase 
was not detected.(19) This condition could have occurred 
since DHA genes are inducible by β-lactam antibiotics, 
instead of expressed naturally.(6) Therefore the use of 
β-lactam antibiotics must be prudent to avoid an expression 
or even over expression of the ampC plasmid-mediated 
gene. In this study, ampC genes were only detected in 
6 isolates out of 9 confirmed AmpC and AmpC/ESBL 
producers.  This result could be due to the fact that of ampC 
gene family continue to expand, while the primers used 
in this study were only designated to these 6 ampC gene 
families. In addition, they also exist as varian i.e., the varian 
for the DHA are DHA-1 and DHA-2, the CIT are CMY-
2 and CMY-4, the EBC are ACT-1 and MIR-1 and many 
more. There were some constraints in the present study, 
among other β-lactamase standard microorganisms for the 
DDS test was not available. Number of AmpC and AmpC/
ESBL isolates positive from the DDS test was too low, 
which then might not show the presence of all ampC gene 
family has ever reported by PCR. 
Conclusion
This study showed the AmpC and AmpC/ESBL-producing 
Enterobacteriaceae were simultaneously co-exist in the 
ICU of Cipto Mangunkusumo Hospital. Three ampC gene 
families, DHA, EBC and CIT were identified. All of the 
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AmpC/ESBL-producing isolates showed resistance to 
almost all antibiotic tested except for Amikacin. Therefore, 
the use of antibiotics for the treatment of the patients with 
infection in the ICU must be prudent to prevent the increase 
and the spread of the multi-drug resistant bacteria.
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